$1.14 Billion is the total value of FRAZIER MANAGEMENT LLC's 26 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 12.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $318,814,000 | +1.5% | 10,542,790 | 0.0% | 28.00% | -21.4% | |
| PHAT | Sell | PHATHOM PHARMACEUTICALS INC | $191,780,000 | +2.0% | 5,827,415 | -20.0% | 16.84% | -21.0% |
| PASG | PASSAGE BIO INC | $136,902,000 | +73.5% | 5,009,219 | 0.0% | 12.02% | +34.4% | |
| PCVX | New | VAXCYTE INC | $73,005,000 | – | 2,309,554 | +100.0% | 6.41% | – |
| MIRM | MIRUM PHARMACEUTICALS INC | $69,412,000 | +39.0% | 3,566,912 | 0.0% | 6.10% | +7.6% | |
| ANAB | ANAPTYSBIO INC | $51,749,000 | +58.1% | 2,316,447 | 0.0% | 4.54% | +22.4% | |
| TBIO | TRANSLATE BIO INC | $39,116,000 | +79.7% | 2,182,789 | 0.0% | 3.44% | +39.2% | |
| KRYS | KRYSTAL BIOTECH INC | $37,071,000 | -4.2% | 895,000 | 0.0% | 3.26% | -25.8% | |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $36,042,000 | -31.2% | 1,312,999 | -25.0% | 3.16% | -46.7% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $30,005,000 | +140.3% | 1,437,028 | +12.4% | 2.64% | +86.1% |
| ALPN | ALPINE IMMUNE SCIENCES INC | $24,969,000 | +237.1% | 2,571,450 | 0.0% | 2.19% | +161.1% | |
| Buy | TRILLIUM THERAPEUTICS INC | $22,288,000 | +133.3% | 2,755,000 | +12.7% | 1.96% | +80.7% | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $19,563,000 | +80.0% | 1,320,045 | +33.2% | 1.72% | +39.4% |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $16,514,000 | +7.2% | 943,666 | 0.0% | 1.45% | -17.0% | |
| GRTS | GRITSTONE ONCOLOGY INC | $13,690,000 | +14.1% | 2,061,758 | 0.0% | 1.20% | -11.6% | |
| APTX | APTINYX INC | $13,303,000 | +93.0% | 3,190,079 | 0.0% | 1.17% | +49.6% | |
| ISEE | New | IVERIC BIO INC | $12,059,000 | – | 2,364,500 | +100.0% | 1.06% | – |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $11,051,000 | +277.2% | 528,000 | +151.4% | 0.97% | +192.2% |
| ALNA | ALLENA PHARMACEUTICALS INC | $5,262,000 | +64.2% | 3,330,373 | 0.0% | 0.46% | +27.3% | |
| CDTX | CIDARA THERAPEUTICS INC | $4,842,000 | +48.8% | 1,312,258 | 0.0% | 0.42% | +15.2% | |
| NABRIVA THERAPEUTICS PLC | $2,871,000 | +17.3% | 4,256,526 | 0.0% | 0.25% | -9.4% | ||
| SRRA | SIERRA ONCOLOGY INC | $2,454,000 | +23.2% | 202,803 | 0.0% | 0.22% | -4.9% | |
| VTVT | VTV THERAPEUTICS INCcl a | $2,390,000 | +17.9% | 1,062,000 | 0.0% | 0.21% | -8.7% | |
| ITRM | ITERUM THERAPEUTICS PLC | $1,831,000 | -56.1% | 1,538,316 | 0.0% | 0.16% | -66.0% | |
| ETTX | Sell | ENTASIS THERAPEUTICS HLDGS I | $1,036,000 | -62.7% | 349,953 | -66.7% | 0.09% | -71.1% |
| BELLICUM PHARMACEUTICALS INC | $781,000 | +57.8% | 105,144 | 0.0% | 0.07% | +23.2% | ||
| MLND | Exit | MILLENDO THERAPEUTICS INC | $0 | – | -1,396,615 | -100.0% | -0.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-04
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.